AXSM: Axsome Therapeutics Inc Price to Earnings Multiple
Axsome Therapeutics (AXSM) leverages the high demand for unique CNS therapy combinations while adhering to strict environmental waste disposal regulations. The P/E ratio dynamics help assess the asset's margin of safety, where -44.70 indicates the value of this parameter. The company's active R&D pipeline is accelerating the commercialization of new treatments for migraine, depression, and narcolepsy.
Comprehensive metric breakdowns and analytics for Axsome Therapeutics Inc (AXSM)
- price and consensus price forecast:
- market capitalization information:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Axsome Therapeutics|AXSM - Long-Term Debt to Capital|Current Liabilities to Capital Axsome Corp|AXSM - Company Total Debt|Debt to Net Assets Ratio Axsome Therapeutics, Inc.|AXSM - Company Long-Term Liabilities|Amount of Current Liabilities Axsome Therapeutics|Intermediate Coverage Ratio axsome.com
- earnings and market multiples details:
AXSM - Net Profit|Expected Net Profit Axsome Therapeutics|AXSM - Price to Earnings Ratio|Future Price to Earnings Multiple Axsome|AXSM - PEG Multiple|EV/EBITDA Multiple Axsome Therapeutics, Inc.|AXSM - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Axsome Therapeutics|AXSM - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months axsome.com|AXSM - Net earnings per share growth this year|Earnings growth forecast for next year Axsome Therapeutics
General company analysis:axsome.com - AXSM
The P/E ratio reflects the market value of each unit of net income, allowing for an assessment of the premium paid for future business growth. By analyzing the forward P/E of Axsome Therapeutics (AXSM), an investor separates fundamental value from volatility, which is critical for Axsome Therapeutics (AXSM), as its production outsourcing model minimizes capital expenditures and environmental risks, focusing the valuation exclusively on the efficiency of neuro-drug development.
Competing companies
P/E Multiple biogen.com|Price to Earnings Ratio NBIX (Neurocrine Biosciences, Inc.)|Regencell Bioscience Ltd - Price to Earnings Multiple|Price to Earnings Ratio ACADIA Pharmaceuticals Inc ACAD|Business Payback Period Xenon Corp (XENE)|VKTX - Price to Earnings Ratio|Market Cap to Earnings supernus.com|Catalyst Pharmaceuticals, Inc. (CPRX) - Price to Earnings Ratio|Price to Earnings Ratio Denali|HRMY (Harmony Pharma) - P/E Multiple|Market Cap to Earnings Biohaven Corp BHVN|Price to Earnings Ratio AMLX (Amylyx Pharmaceuticals)|TRVI (trevitherapeutics.com) - Company Value to Net Income|Praxis Precision Medicines, Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio AVXL (Anavex)|CeriBell Corp - P/E Multiple|Company Value to Net Income PRTA (Prothena Corporation)|ALEC: P/E Multiple|Market Cap to Earnings annexonbio.com (ANNX)|Price to Earnings Ratio Omeros Corp|NGNE: Company Value to Net Income|P/E Multiple ACIU|P/E Multiple Voyager Corp (VYGR)|Price to Earnings Ratio Neumora Therapeutics NMRA|SCLX (scilexholding.com) - Market Cap to Net Income|Tevogen Bio - P/E Multiple|Market Cap to Earnings Alpha Cognition|CGTX (Cognition Therapeutics, Inc.) - Price to Earnings Ratio|Inhibikase Pharma (IKT) - P/E Multiple|Price to Earnings Ratio SAVA|ASRT (Assertio Therapeutics) - Market Price to Net Income Ratio|P/E Multiple COYA|Business Payback Period vistagen.com|P/E Multiple OVID (Ovid Therapeutics)|ABOS - Price to Earnings Ratio|CRVO - Price to Earnings Ratio|Business Payback Period Alterity Therapeutics ATHE|CLNN: P/E Multiple|PepGen (PEPG) - P/E Multiple|Price to Earnings Ratio JUNS|Price to Earnings Multiple RLMD (Relmada Corp)|Price to Earnings Ratio Annovis Bio, Inc. (ANVS)|Business Payback Period gracetx.com|Price to Earnings Ratio Firefly Neuroscience AIFF|KLTO - Price to Earnings Ratio|NRSN - Price to Earnings Ratio|RVPH (Reviva Pharmaceuticals, Inc.) - Price to Earnings Multiple|MTVA: P/E Multiple|Market Cap to Earnings neuraxis.com (NRXS)|Price to Earnings Ratio HSDT|P/E Multiple Passage Bio Corp|Price to Earnings Ratio Neuphoria Therapeutics Inc. (NEUP)|NERV (Minerva) - Company Value to Net Income|Price to Earnings Ratio Athira Pharma, Inc. ATHA|addextherapeutics.com (ADXN) - Market Cap to Earnings|Alzamend - P/E Multiple|CYCN - P/E Multiple|PTIX (protagenic.com) - Price to Earnings Ratio|Price to Earnings Multiple KTTA|Price to Earnings Ratio Cortigent Inc|avenuetx.com (ATXI) - Business Payback Period|Price to Earnings Ratio BrainStorm Cell Therapeutics (BCLI)|CARA - Market Cap to Earnings|Price to Earnings Ratio Chromocell Therapeutics Corporation CHRO|ELYM - Price to Earnings Ratio|Intra-Cellular - P/E Multiple|Market Cap to Earnings longboardpharma.com|MRNS (Marinus Pharmaceuticals, Inc.) - Price to Earnings Ratio|NKGen Biotech Inc - Company Value to Net Income|Price to Earnings Ratio NRBO|SAGE (Sage Therapeutics Inc) - Market Price to Net Income Ratio|P/E Multiple SNPX|TRVN (trevena.com) - Company Value to Net Income|P/E Multiple VIGL (Vigil Neuroscience, Inc.)|anewmeds.com (WENA) - Market Cap to Earnings|CERE - Price to Earnings Ratio
